Ignite Creation Date:
2025-12-24 @ 12:31 PM
Ignite Modification Date:
2025-12-28 @ 5:11 AM
Study NCT ID:
NCT03430661
Status:
COMPLETED
Last Update Posted:
2025-07-03
First Post:
2018-01-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C000601315', 'term': 'selatogrel'}, {'id': 'D000077144', 'term': 'Clopidogrel'}, {'id': 'D000068799', 'term': 'Prasugrel Hydrochloride'}, {'id': 'D000077486', 'term': 'Ticagrelor'}], 'ancestors': [{'id': 'D013988', 'term': 'Ticlopidine'}, {'id': 'D058924', 'term': 'Thienopyridines'}, {'id': 'D013876', 'term': 'Thiophenes'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D011725', 'term': 'Pyridines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D010879', 'term': 'Piperazines'}, {'id': 'D000241', 'term': 'Adenosine'}, {'id': 'D011684', 'term': 'Purine Nucleosides'}, {'id': 'D011687', 'term': 'Purines'}, {'id': 'D009705', 'term': 'Nucleosides'}, {'id': 'D009706', 'term': 'Nucleic Acids, Nucleotides, and Nucleosides'}, {'id': 'D012263', 'term': 'Ribonucleosides'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'OTHER', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 77}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2018-01-24', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-11', 'completionDateStruct': {'date': '2019-05-29', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-07-01', 'studyFirstSubmitDate': '2018-01-30', 'studyFirstSubmitQcDate': '2018-02-06', 'lastUpdatePostDateStruct': {'date': '2025-07-03', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2018-02-13', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-05-20', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Time-matched comparisons of IPA% (MPA) between treatments (i.e., Treatment A1 vs A2, Treatment B1 vs B2, and treatment C1 vs C2, treatments are defined below) following administration of ACT-246475 and its matching placebo.', 'timeFrame': 'From baseline up to 48 hours', 'description': '\\- IPA%\\[MPA\\] will be calculated as mean change in percentage from baseline for each time point.'}, {'measure': 'Time-matched comparisons of IPA %(PRU) between treatments (i.e., Treatment A1 vs A2, Treatment B1 vs B2, and treatment C1 vs C2) following administration of ACT-246475 and its matching placebo.', 'timeFrame': 'From baseline up to 48 hours', 'description': '\\- IPA%\\[PRU\\] will be calculated as mean change in percentage from baseline for each time point.\n\nTreatment A1: single s.c. dose administration of ACT-246475-matching placebo followed by a single oral dose of clopidogrel (600 mg).\n\nTreatment A2: single s.c. dose administration (16 mg) of ACT-246475 followed by a single oral dose of clopidogrel (300 mg).\n\nTreatment B1: single s.c. dose administration of ACT-246475-matching placebo followed by a single oral dose of prasugrel (60 mg).\n\nTreatment B2: single s.c. dose administration (16 mg) of ACT-246475 followed by a single oral dose of prasugrel (60 mg).\n\nTreatment C1: single s.c. dose administration of ACT-246475-matching placebo followed by a single oral dose of ticagrelor (180 mg).\n\nTreatment B2: single s.c. dose administration (16 mg) of ACT-246475 followed by a single oral dose of ticagrelor (180 mg).'}]}, 'oversightModule': {'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Healthy']}, 'referencesModule': {'references': [{'pmid': '33412611', 'type': 'RESULT', 'citation': 'Schilling U, Dingemanse J, Dobrow M, Baumann M, Riederer MA, Juif PE, Ufer M. Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor. Thromb Haemost. 2021 Jun;121(6):755-766. doi: 10.1055/s-0040-1721773. Epub 2021 Jan 7.'}]}, 'descriptionModule': {'briefSummary': 'The primary objective of this study is to assess the pharmacodynamic (PD) effects of clopidogrel, prasugrel, and ticagrelor when administered after a single subcutaneous (s.c.) dose of ACT-246475 in healthy male and female subjects'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Main Inclusion Criteria:\n\n* Signed informed consent\n* Healthy male and female subjects aged between 18 and 65 years (inclusive) at screening\n* Body mass index of 18.0 to 31.0 kg/m2 (inclusive) at Screening\n* Women of childbearing potential must have a negative serum pregnancy test and use reliable birth controls from screening up to at least 30 days after last study treatment administration\n* Systolic blood pressure (SBP) 100-140 mmHg, diastolic blood pressure (DBP) 50-90 mmHg, and pulse rate 50-90 beats per minute (bpm) (inclusive) at screening\n* Healthy on the basis of physical examination, cardiovascular assessments, and laboratory tests\n* Maximum (at peak) platelet aggregation ≥ 40% (light transmission aggregometry \\[LTA\\]) upon 20 μM adenosine diphosphate (ADP) activation at screening\n* Values of closure time tested with the Platelet Function Analyzer (PFA) equipment, for both cartridges of collagen/adrenaline and collagen/ADP below the upper limit of normal range at screening\n\nMain Exclusion Criteria:\n\n* Pregnant or lactating women\n* Known hypersensitivity to ACT-246475, clopidogrel, prasugrel, ticagrelor, any of their excipients, or drugs of the same class\n* Any contraindication to clopidogrel, prasugrel, or ticagrelor treatment\n* Known hypersensitivity or allergy to natural rubber latex\n* Platelet count \\< 120 × 109 L-1 at Screening and Day -1\n* Known platelet disorders (e.g., Glanzmann thromboasthenia, von Willebrand disease, platelet release defect)\n* Previous treatment with acetylsalicylate, non-steroidal anti-inflammatory drugs, P2Y12 receptor antagonists, or any medication with blood-thinning activity (i.e., injectable or oral anticoagulants) within 3 weeks prior to study treatment administration\n* Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol'}, 'identificationModule': {'nctId': 'NCT03430661', 'briefTitle': 'A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects', 'organization': {'class': 'INDUSTRY', 'fullName': 'Viatris Inc.'}, 'officialTitle': 'Single-center, Double-blind (ACT-246475), Open-label (Clopidogrel, Prasugrel, and Ticagrelor), Placebo-controlled, Randomized, Two-way Crossover Study to Investigate the Pharmacodynamics, Safety, and Tolerability of a Single Oral Dose of Clopidogrel or, Prasugrel, or Ticagrelor When Administered After a Single Subcutaneous Dose of the P2Y12 Antagonist ACT-246475 in Healthy Male and Female Subjects', 'orgStudyIdInfo': {'id': 'ID-076-103'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Part A: Group 1', 'description': 'Clopidogrel will be administered 0.5 h after ACT-246475 or placebo, i.e., at the time of tmax', 'interventionNames': ['Drug: ACT-246475', 'Drug: Clopidogrel', 'Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Part A: Group 2', 'description': 'Clopidogrel will be administered 12 h after ACT-246475 or placebo', 'interventionNames': ['Drug: ACT-246475', 'Drug: Clopidogrel', 'Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Part A: Group 3', 'description': 'Any time interval up to 24 h between the administration of ACT-246475 or placebo and clopidogrel may be studied', 'interventionNames': ['Drug: ACT-246475', 'Drug: Clopidogrel', 'Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Part B: Group 1', 'description': 'Prasugrel will be administered 12 h after ACT-246475 or placebo', 'interventionNames': ['Drug: ACT-246475', 'Drug: Prasugrel', 'Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Part B: Group 2', 'description': 'Any time interval up to 24 h between the administration of ACT-246475 or placebo and prasugrel may be studied', 'interventionNames': ['Drug: ACT-246475', 'Drug: Prasugrel', 'Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Part B: Group 3', 'description': 'Any time interval up to 24 h between the administration of ACT-246475 or placebo and prasugrel may be studied', 'interventionNames': ['Drug: ACT-246475', 'Drug: Prasugrel', 'Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Part C: Group 1', 'description': 'Ticagrelor will be administered 0.5 h after ACT-246475 or placebo, i.e., at the time of tmax', 'interventionNames': ['Drug: ACT-246475', 'Drug: Placebo', 'Drug: Ticagrelor']}, {'type': 'EXPERIMENTAL', 'label': 'Part C: Group 2', 'description': 'Any time interval up to 24 h between the administration of ACT-246475 or placebo and ticagrelor may be studied', 'interventionNames': ['Drug: ACT-246475', 'Drug: Placebo', 'Drug: Ticagrelor']}, {'type': 'EXPERIMENTAL', 'label': 'Part C: Group 3', 'description': 'Any time interval up to 24 h between the administration of ACT-246475 or placebo and ticagrelor may be studied', 'interventionNames': ['Drug: ACT-246475', 'Drug: Placebo', 'Drug: Ticagrelor']}], 'interventions': [{'name': 'ACT-246475', 'type': 'DRUG', 'description': 'Lyophilized ACT-246475A to be reconstituted with 1 mL of water for injection', 'armGroupLabels': ['Part A: Group 1', 'Part A: Group 2', 'Part A: Group 3', 'Part B: Group 1', 'Part B: Group 2', 'Part B: Group 3', 'Part C: Group 1', 'Part C: Group 2', 'Part C: Group 3']}, {'name': 'Clopidogrel', 'type': 'DRUG', 'description': 'Tablet for oral administration (300 or 600 mg)', 'armGroupLabels': ['Part A: Group 1', 'Part A: Group 2', 'Part A: Group 3']}, {'name': 'Prasugrel', 'type': 'DRUG', 'description': 'Tablet for oral administration (60 mg)', 'armGroupLabels': ['Part B: Group 1', 'Part B: Group 2', 'Part B: Group 3']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Matching ACT-246475 placebo will consist of sterile 0.9% w/v sodium chloride solution', 'armGroupLabels': ['Part A: Group 1', 'Part A: Group 2', 'Part A: Group 3', 'Part B: Group 1', 'Part B: Group 2', 'Part B: Group 3', 'Part C: Group 1', 'Part C: Group 2', 'Part C: Group 3']}, {'name': 'Ticagrelor', 'type': 'DRUG', 'description': 'Tablet for oral administration (180 mg)', 'armGroupLabels': ['Part C: Group 1', 'Part C: Group 2', 'Part C: Group 3']}]}, 'contactsLocationsModule': {'locations': [{'zip': '07103', 'city': 'Newark', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Biotrial Inc', 'geoPoint': {'lat': 40.73566, 'lon': -74.17237}}], 'overallOfficials': [{'name': 'Clinical Trials', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Viatris Innovation GmbH'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Viatris Innovation GmbH', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}